RxDoctor Payments Data

Snehitha Vijaykumar, MD

Interventional Cardiology · Ames, IANPI 1376960526

Payments from drug & device makers

What this record shows

This record is dominated by grants: $8,605 of the $13,534 with a category attached, or 63.6%. 22 manufacturers reported payments, led by Medtronic at 59.2% of the total. Reporting peaked in 2020 at $8,958 and has fallen 99.0% since, to $86 in 2025.

$13,534in general payments, 2019–2025

Across 118 payments — averaging $114.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$8K
  • Abbott$2K
  • Boston Scientific$1K
  • Edwards Lifesciences$931
  • Cardiovascular Systems Inc.$441
  • Shockwave Medical, Inc$243
  • plus $1K from 16 others

What the payments were for

  • Grants$8,60564%
  • Travel & lodging$1,0087%
  • Food & beverage$3,62827%
  • Education$2942%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,534 in reported general payments places this provider in the 75th percentile of 64 interventional cardiology providers in Iowa.

See all interventional cardiology providers in Iowa

Medicare billing

Part B allowed, 2024
$154,851
Medicare patients
1,194
Services billed
2,543

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban195$174,759
XareltoRivaroxaban31$34,166
BrilintaTicagrelor35$26,295
JardianceEmpagliflozin27$18,310
EntrestoSacubitril/Valsartan12$13,881
Dabigatran EtexilateDabigatran Etexilate Mesylate13$3,478
Ranolazine ErRanolazine19$3,162
Metoprolol Succinate240$2,941
Atorvastatin Calcium177$1,431
Diltiazem 24hr Er (Cd)Diltiazem Hcl53$1,215
Bumetanide15$778
ClopidogrelClopidogrel Bisulfate95$631
Losartan Potassium79$604
Isosorbide Mononitrate ErIsosorbide Mononitrate58$579
Ezetimibe24$468

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$62$174,759195 claims
Johnson & JohnsonXarelto$28$34,16631 claims
AstraZenecaBrilinta$154$26,29535 claims
Boehringer IngelheimJardiance$125$18,31027 claims
NovartisEntresto$45$13,88112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 64 interventional cardiology providers in Iowa.

Other interventional cardiology in Ames

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →